Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers - PubMed

Affiliations

• PMID: 27088920
• DOI: 10.1111/imr.12405

Review

Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers

Marie-Caroline Dieu-Nosjean et al. Immunol Rev. 2016 May.

Abstract

The characterization of the microenvironment of human tumors led to the description of tertiary lymphoid structures (TLS) characterized by mature dendritic cells in a T-cell zone adjacent to B-cell follicle including a germinal center. TLS represent sites of lymphoid neogenesis that develop in most solid cancers. Analysis of the current literature shows that the TLS presence is associated with a favorable clinical outcome for cancer patients, regardless of the approach used to quantify TLS and the stage of the disease. Using several approaches that combine immunohistochemistry, gene expression assays, and flow cytometry on large series of lung tumors, our work demonstrated that TLS are important sites for the initiation and/or maintenance of the local and systemic T- and B-cell responses against tumors. Surrounded by high endothelial venules, they represent a privileged area for the recruitment of lymphocytes into tumors and generation of central-memory T and B cells that circulate and limit cancer progression. TLS can be considered as a novel biomarker to stratify the overall survival risk of untreated cancer patients and as a marker of efficient immunotherapies. The induction and manipulation of cancer-associated TLS using drug agonists and/or biotherapies should open new avenues to treat cancer patients.

Keywords: CD8+ T cell; anti-tumor response; biomarker; clear cell renal cell carcinoma; non-small-cell lung cancer; tertiary lymphoid structure.

Similar articles

• Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells.

  Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S, de Chaisemartin L, Ouakrim H, Becht E, Alifano M, Validire P, Remark R, Hammond SA, Cremer I, Damotte D, Fridman WH, Sautès-Fridman C, Dieu-Nosjean MC. Goc J, et al. Cancer Res. 2014 Feb 1;74(3):705-15. doi: 10.1158/0008-5472.CAN-13-1342. Epub 2013 Dec 23. Cancer Res. 2014. PMID: 24366885

• Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer.

  Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, Lepelley A, Becht E, Katsahian S, Bizouard G, Validire P, Damotte D, Alifano M, Magdeleinat P, Cremer I, Teillaud JL, Fridman WH, Sautès-Fridman C, Dieu-Nosjean MC. Germain C, et al. Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44. doi: 10.1164/rccm.201309-1611OC. Am J Respir Crit Care Med. 2014. PMID: 24484236

• Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer.

  de Chaisemartin L, Goc J, Damotte D, Validire P, Magdeleinat P, Alifano M, Cremer I, Fridman WH, Sautès-Fridman C, Dieu-Nosjean MC. de Chaisemartin L, et al. Cancer Res. 2011 Oct 15;71(20):6391-9. doi: 10.1158/0008-5472.CAN-11-0952. Epub 2011 Sep 7. Cancer Res. 2011. PMID: 21900403

• Tertiary lymphoid tissue in the tumor microenvironment: from its occurrence to immunotherapeutic implications.

  Di Caro G, Castino GF, Bergomas F, Cortese N, Chiriva-Internati M, Grizzi F, Mantovani A, Marchesi F. Di Caro G, et al. Int Rev Immunol. 2015 Mar;34(2):123-33. doi: 10.3109/08830185.2015.1018416. Int Rev Immunol. 2015. PMID: 25901857 Review.

• Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer.

  Sautès-Fridman C, Verneau J, Sun CM, Moreira M, Chen TW, Meylan M, Petitprez F, Fridman WH. Sautès-Fridman C, et al. Semin Immunol. 2020 Apr;48:101406. doi: 10.1016/j.smim.2020.101406. Epub 2020 Nov 25. Semin Immunol. 2020. PMID: 33248905 Review.

Cited by

• CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.

  Zhang QF, Li J, Jiang K, Wang R, Ge JL, Yang H, Liu SJ, Jia LT, Wang L, Chen BL. Zhang QF, et al. Theranostics. 2020 Aug 25;10(23):10619-10633. doi: 10.7150/thno.44871. eCollection 2020. Theranostics. 2020. PMID: 32929370 Free PMC article.

• PTEN loss correlates with T cell exclusion across human cancers.

  Lin Z, Huang L, Li SL, Gu J, Cui X, Zhou Y. Lin Z, et al. BMC Cancer. 2021 Apr 19;21(1):429. doi: 10.1186/s12885-021-08114-x. BMC Cancer. 2021. PMID: 33874915 Free PMC article.

• Spatially aware dimension reduction for spatial transcriptomics.

  Shang L, Zhou X. Shang L, et al. Nat Commun. 2022 Nov 23;13(1):7203. doi: 10.1038/s41467-022-34879-1. Nat Commun. 2022. PMID: 36418351 Free PMC article.

• The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling.

  Meneveau MO, Kumar P, Lynch KT, Patel SP, Slingluff CL. Meneveau MO, et al. J Immunother Cancer. 2022 Mar;10(3):e003533. doi: 10.1136/jitc-2021-003533. J Immunother Cancer. 2022. PMID: 35277457 Free PMC article.

• Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer.

  Weinstein AM, Giraldo NA, Petitprez F, Julie C, Lacroix L, Peschaud F, Emile JF, Marisa L, Fridman WH, Storkus WJ, Sautès-Fridman C. Weinstein AM, et al. Cancer Immunol Immunother. 2019 Jan;68(1):109-120. doi: 10.1007/s00262-018-2259-0. Epub 2018 Oct 12. Cancer Immunol Immunother. 2019. PMID: 30315348 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program